Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Depressive personality disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Depressive personality disorder. Displaying page 1 of 1.
    EudraCT Number: 2010-020956-69 Sponsor Protocol Number: OX02 Start Date*: 2011-02-23
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung
    Medical condition: ICD-10 F60.3 Emotionally unstable personality disorder Two types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline typ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002577-22 Sponsor Protocol Number: COMP003 Start Date*: Information not available in EudraCT
    Sponsor Name:COMPASS Pathfinder, Limited
    Full Title: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression
    Medical condition: treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005320-17 Sponsor Protocol Number: CL3-20098-060 Start Date*: 2012-06-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre stu...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001692-37 Sponsor Protocol Number: ketamine_plus_CBASP Start Date*: 2021-02-24
    Sponsor Name:University Hospital Tuebingen
    Full Title: Pharmacologic treatment augmentation in chronic depression randomized, controlled, double blinded, phase II study
    Medical condition: Males and females between 18-64 years with a diagnosis of chronic depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10066555 Chronic depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001529-24 Sponsor Protocol Number: 190-062 Start Date*: 2007-03-06
    Sponsor Name:Sepracor NV in care of Sepracor Inc.
    Full Title: Adults adminstered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered with Venlafaxine in Subjects wit...
    Medical condition: Insomnia Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) GB (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003288-36 Sponsor Protocol Number: COMP001 Start Date*: 2018-03-09
    Sponsor Name:COMPASS Pathways, Ltd
    Full Title: The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)
    Medical condition: Treatment-Resistant Depression (P-TRD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) IE (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004210-26 Sponsor Protocol Number: 14/0647 Start Date*: 2016-11-22
    Sponsor Name:PRIMENT Clinical Trials Unit, UCL
    Full Title: A Phase IV double blind multi-site, individually randomised parallel group controlled trial investigating the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in pati...
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000024331 10066555 Chronic depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005200-15 Sponsor Protocol Number: 6096-022 Start Date*: 2012-05-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.
    Medical condition: depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10066555 Chronic depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2006-002880-19 Sponsor Protocol Number: lapaz2006 Start Date*: 2006-09-14
    Sponsor Name:Servicio de psiquiatria. Hospital Universitario La Paz
    Full Title: Comparación de dos estrategias de intervención para el tratamiento de los trastornos depresivos en pacientes oncológicos
    Medical condition: Major depressive Disorder, one episode or several episodes. ICD: 296.2x, 296.3x
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000453-35 Sponsor Protocol Number: EPO-AD-01-2008 Start Date*: 2008-06-30
    Sponsor Name:Max-Planck-Institute of Experimental Medicine
    Full Title: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)
    Medical condition: Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type LLT
    9.1 10066555 Chronic depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016713-20 Sponsor Protocol Number: CL2-20098-072 Start Date*: 2010-04-13
    Sponsor Name:Laboratorios Servier S.L.
    Full Title: Eficacia de agomelatina 25mg/día (con posibilidad de incremento a 50mg/día tras 8 semanas de tratamiento) por vía oral durante 16 semanas en pacientes con Trastorno Obsesivo Compulsivo // Efficacy...
    Medical condition: Trastorno Obsesivo Compulsivo // Obsessive-compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001490-15 Sponsor Protocol Number: RIS-BMN-3001 Start Date*: 2007-04-23
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the...
    Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 Bipolar I disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000219-18 Sponsor Protocol Number: PsiloRCT001 Start Date*: 2018-04-09
    Sponsor Name:Imperial College London
    Full Title: Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000043-74 Sponsor Protocol Number: PNAS0122 Start Date*: 2023-07-27
    Sponsor Name:Medical University of Vienna
    Full Title: Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications
    Medical condition: major depressive disorder poor neonatal adaptation syndrome (after antidepressant use during pregnancy)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 13:53:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA